Strut Position, Blood Flow, and Drug Deposition: Implications for Single and Overlapping Drug-Eluting Stents

2007 ◽  
Vol 2007 ◽  
pp. 18-19
Author(s):  
P.K. Henke
Keyword(s):  
Blood Flow ◽  
Drug Eluting Stents ◽  
Drug Deposition ◽  
Drug Eluting

The Localized Hemodynamics of Drug-Eluting Stents Are Not Improved by the Presence of Magnetic Struts

2016 ◽  
Vol 139 (1) ◽  
Author(s):  
P. R. S. Vijayaratnam ◽  
T. J. Barber ◽  
J. A. Reizes
Keyword(s):  
Blood Flow ◽  
Stent Thrombosis ◽  
Separated Flow ◽  
Drug Eluting Stents ◽  
Magnetic Flux Density ◽  
Drug Eluting Stent ◽  
Shear Stresses ◽  
Stent Strut ◽  
Drug Eluting ◽  
Wall Shear

The feasibility of implementing magnetic struts into drug-eluting stents (DESs) to mitigate the adverse hemodynamics which precipitate stent thrombosis is examined. These adverse hemodynamics include platelet-activating high wall shear stresses (WSS) and endothelial dysfunction-inducing low wall shear stresses. By magnetizing the stent struts, two forces are induced on the surrounding blood: (1) magnetization forces which reorient red blood cells to align with the magnetic field and (2) Lorentz forces which oppose the motion of the conducting fluid. The aim of this study was to investigate whether these forces can be used to locally alter blood flow in a manner that alleviates the thrombogenicity of stented vessels. Two-dimensional steady-state computational fluid dynamics (CFD) simulations were used to numerically model blood flow over a single magnetic drug-eluting stent strut with a square cross section. The effects of magnet orientation and magnetic flux density on the hemodynamics of the stented vessel were elucidated in vessels transporting oxygenated and deoxygenated blood. The simulations are compared in terms of the size of separated flow regions. The results indicate that unrealistically strong magnets would be required to achieve even modest hemodynamic improvements and that the magnetic strut concept is ill-suited to mitigate stent thrombosis.

scholarly journals Drug deposition in coronary arteries with overlapping drug-eluting stents

2016 ◽  
Vol 238 ◽  
pp. 1-9 ◽  
Author(s):  
Farhad Rikhtegar ◽  
Elazer R. Edelman ◽  
Ufuk Olgac ◽  
Dimos Poulikakos ◽  
Vartan Kurtcuoglu
Keyword(s):  
Coronary Arteries ◽  
Drug Eluting Stents ◽  
Drug Deposition ◽  
Drug Eluting

scholarly journals Drug Eluting Stents & Coronary Angiography

2006 ◽  
Vol 4 (1) ◽  
pp. 27-31
Author(s):  
Bharat Rawat ◽  
PR Poudel ◽  
Smriti Mulmi
Keyword(s):  
Blood Flow ◽  
Coronary Artery ◽  
Coronary Angiography ◽  
Human Heart ◽  
Drug Eluting Stents ◽  
Drug Eluting ◽  
German Physician

Twenty-five years ago, a young German physician, Andreas Gruentzig, inserted a catheter into a 38-year-old man's coronary artery, inflated a tiny balloon the doctor had fashioned in his own kitchen, successfully opening a blockage and restoring blood flow to a human heart. This event set a cascade of newer invention.

scholarly journals How does vessel curvature influence drug release from DES and drug transport in arterial tissue?

2019 ◽  
Vol 7 ◽  
Author(s):  
Javier Escuer Gracia ◽  
Estefanía Peña ◽  
Irene Aznar ◽  
Miguel Ángel Martínez
Keyword(s):  
Blood Flow ◽  
Drug Release ◽  
Drug Transport ◽  
Computational Models ◽  
Arterial Wall ◽  
Drug Eluting Stents ◽  
Complex Geometries ◽  
Arterial Tissue ◽  
Drug Eluting ◽  
Vessel Curvature

Several computational models of transport of drugs eluted from drug-eluting stents (DES) in curved arteries were developed in order to investigate the influence of the arterial curvature and complex geometries on drug transport in the blood flow and in the arterial wall.

Drug-Eluting Stents Equal on Thrombosis

2012 ◽  
Vol 45 (14) ◽  
pp. 8
Author(s):  
MICHELE G. SULLIVAN
Keyword(s):  
Drug Eluting Stents ◽  
Drug Eluting

Drug-eluting stents for treatment of focal infrapopliteal lesions

VASA ◽  
2012 ◽  
Vol 41 (2) ◽  
pp. 90-95 ◽  
Author(s):  
Rastan ◽  
Noory ◽  
Zeller
Keyword(s):  
Limb Salvage ◽  
Bare Metal Stents ◽  
Target Lesion ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Target Lesion Revascularisation ◽  
Randomized Studies ◽  
Drug Eluting ◽  
The Mean

We have investigated the role of drug-eluting stents on patency rates after treatment of focal infrapopliteal lesions in patients with intermittent claudication and critical limb ischemia. Reports indicate that drug-eluting stents reduce the risk of restenosis after percutaneous infrapopliteal artery revascularization. A Pub Med, EMBASE, Cochrane database review search of non-randomized studies investigating patency rates, target lesion revascularisation rates, limb salvage rates and mortality rates in an up to 3-year follow-up period after drug-eluting stent placement was conducted. In addition, preliminary results of randomized studies comparing drug-eluting stents with bare-metal stents and plain balloon angioplasty in treatment of focal infrapopliteal lesions were included in this review. A total of 1039 patients from 10 non-randomized and randomized studies were included. Most commonly used drug-eluting stents were sirolimus-eluting. The mean follow-up period was 12.6 (range 8 - 24). The mean 1-year primary patency rate was 86 ± 5 %. The mean target lesion revascularization rate and limb salvage rate was 9.9 ± 5 % and 96.6 %±4 %, respectively. Results from non-randomized and preliminary results from prospective, randomized trials show a significant advantage for drug-eluting stents in comparison to plain balloon angioplasty and bare-metal stents concerning target lesion patency and in parts target lesion revascularisation. No trial reveals an advantage for drug-eluting stents with regard to limb salvage and mortality.

Sign in / Sign up

Export Citation Format

Share Document